Fifth Third Wealth Advisors’s United Therapeutics UTHR Stock Holding History

Fifth Third Wealth Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,208	Closed	-$506K	–	836
2025 Q3	$506K	Buy	1,208 +17	+1%	+$5.72K	0.02%	376
2025 Q2	$342K	Buy	1,191 +3	+0.3%	+$897	0.01%	481
2025 Q1	$366K	Buy	1,188 +4	+0.3%	+$1.37K	0.02%	422
2024 Q4	$418K	Sell	1,184 -304	-20%	-$112K	0.02%	380
2024 Q3	$533K	Sell	1,488 -59	-4%	-$19.9K	0.03%	292
2024 Q2	$493K	Buy	+1,547	New	+$409K	0.04%	277

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

Fifth Third Wealth Advisors's UTHR Position: Q4 2025 in Review

Fifth Third Wealth Advisors sold out of United Therapeutics (UTHR) in Q4 2025, closing a stake of 1,208 shares — an estimated $506K sold.

Fifth Third Wealth Advisors first reported a position in UTHR in Q2 2024 and held it in 6 quarters. The position peaked at $533K in Q3 2024. 838 funds tracked by Wall St. Rank hold UTHR as of Q4 2025.

Fifth Third Wealth Advisors reported no remaining United Therapeutics position as of Q4 2025 after selling out during the quarter.
Fifth Third Wealth Advisors sold 1,208 United Therapeutics shares in Q4 2025, an estimated $506K.
Fifth Third Wealth Advisors first reported a position in United Therapeutics in Q2 2024 and held it in 6 quarters.
Fifth Third Wealth Advisors's United Therapeutics position peaked at $533K in Q3 2024.
838 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2025.

Based on Fifth Third Wealth Advisors's 13F filing for Q4 2025, filed 15 Jan 2026.